Steve joined Atlas in 2025 after serving as President and COO of Aliada Therapeutics, a clinical-stage company pioneering blood-brain barrier crossing technology to deliver diverse therapeutic cargoes into the brain. Aliada was acquired by AbbVie in December 2024. He began his career in clinical research over 20 years ago and has held leadership positions in development operations and clinical technology/analytics at both Pfizer and Infinity Pharmaceuticals before making the transition to biotech start-ups. Since 2012, Steve has led Development Operations and Program Management at multiple start-up companies incubated at Atlas, helping to guide them through acquisitions or public offerings, including Arteaus Therapeutics (migraine), Annovation BioPharma (sedation and general anesthesia), Rodin Therapeutics (synaptopathies), and Third Harmonic Bio (inflammatory diseases). His development experience includes the design, management, and analysis of Phase 1 first-in-human trials through Phase 3b global registration studies, with expertise in developing and implementing technology to enhance trial analytics and operational efficiency. Steve earned his bachelor’s degree in toxicology from Northeastern University.